IL1B and myocardial infarction: In a large RCT of patients with prior myocardial infarction and elevated high-sensitivity C-reactive protein, the IL-1β antagonist canakinumab 150 mg demonstrated benefit vs. placebo for a composite end point of myocardial infarction, stroke, or cardiovascular death.